Standardization of terminology of virological response in the treatment of chronic hepatitis C: Panel recommendations

Journal of Viral Hepatitis

Volumn 19, Issue 4, 2012, Pages 236-243

  Jacobson, I M ^a   Poordad, F ^b   Brown Jr, R S ^c   Kwo, P Y ^d   Reddy, K R ^e   Schiff, E ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c New York Presbyterian Hospital ^*  (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

direct acting antiviral; genotype 1; lead in dosing; protease inhibitor

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG RESPONSE; DRUG TREATMENT FAILURE; EARLY VIROLOGICAL RESPONSE; END OF TREATMENT RESPONSE; EXTENDED RAPID VIRAL RESPONSE; HEPATITIS C; HUMAN; LIMIT OF DETECTION; NOMENCLATURE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ASSAY; RAPID VIROLOGICAL RESPONSE; REAL TIME POLYMERASE CHAIN REACTION; REBOUND; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; HEPATITIS C, CHRONIC; HUMANS; TERMINOLOGY AS TOPIC; VIRAL LOAD;

EID: 84858295907     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01552.x     Document Type: Article

References (19)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)
3. Halfon P, BourliÃ̈re M, Pénaranda G, Khiri H, Ouzan D,. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006; 44: 2507-2511. (Pubitemid 44092419)
4. Gourlain K, Soulier A, Pellegrin B, et al. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J Clin Microbiol 2005; 43: 1669-1673.
5. Quest Diagnostics Heptimax. Available at: http://www.questdiagnostics. com/hcp/intguide/jsp/showintguidepage.jsp?fn=TS-Heptimax.htm (accessed 30 August 2011).
6. COBAS Taqman HCV test v2.0. Available at: http://molecular.roche.com/ assays/Pages/COBASTaqManHCVTestv20HPS.aspx (accessed 6 September 2011).
7. Abbott press release. Available at: http://www.abbottmolecular.com/ products/infectious-diseases/realtime-pcr/hepatitis-hcv-assay.html (accessed 12 September 2011).
8. Ghany MG, Strader DB, Thomas DL, Seeff LB,; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1371.
9. Jacobson IM, McHutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
10. Sherman KR, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C infection. N Engl J Med 2011; 365: 1014-1024.
11. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis 1 infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
12. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
13. European Medicines Agency. Guideline on the clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C. 2008. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003401.pdf (accessed 3 January 2011).
14. US Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Public hearing: expanded access to direct-acting antiviral agents for the treatment of chronic hepatitis C infection in patients with unmet medical need. 2010. Available at: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM213444.pdf (accessed accessed 30 August 2011).
15. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
16. Pearlman BC, Ehleben C, Saifee C,. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1 infected slow responders. Hepatology 2007; 46: 1688-1694.
17. Ferenci P, Laferi H, Scherzer TM, et al. Austrian Hepatitis Study Group. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response. Gastroenterology 2010; 138: 503-512.
18. Sánchez-Tapias JM, Diago M, Escartin P, et al. TeraViC Study Group. Peginterferon alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2005; 131: 451-460. Erratum in: Gastroenterology 2006; 131: 1363.
19. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47: 43-50. (Pubitemid 351171040)